Filters
Change in cT1 following interventions in MASLD: A systematic review and meta-analysis
Andersson, A., et al. (2025)
Clinical Gastroenterology and Hepatology
Read Summary ▾
Treatment interventions in MASLD significantly reduce liver cT1 by an average of 57 ms, indicating improved liver health. Fibroblast growth factor analogues, GLP-1 receptor agonists, and FXR agonists showed notable effects, while placebo showed no change. These results inform study design, supporting cT1 as a useful non-invasive treatment response marker.
Genetic risk accentuates dietary effects on hepatic steatosis, inflammation and fibrosis in a population-based cohort
Chen, V., et al. (2025)
Journal of Hepatology
Read Summary ▾
Poor diet quality and specific genetic alleles are associated with steatotic liver disease. Diet has a much greater impact on hepatic steatosis in those at higher genetic risk, affecting both liver fat content and cT1 (a measure of fibrosis and inflammation). Thus, dietary interventions may yield greater benefit in genetically susceptible groups.
Liver fibro-inflammation in psoriatic arthritis with MASLD improved by anti-IL-17 treatment: a clinical case
James, L., et al. (2025)
Rheumatology
Read Summary ▾
A 37-year-old woman with psoriatic arthritis and undiagnosed liver disease showed significant reversal of liver fibro-inflammation after 6 months of IL-17A inhibitor (secukinumab) treatment. Quantitative mpMRI and blood tests confirmed improved liver health, suggesting biologic disease-modifying antirheumatic drugs may benefit coexisting metabolic liver disease and psoriatic disease.
Standardized pancreatic MRI-T1 measurement methods: comparison between manual measurement and a semi-automated pipeline with automatic quality control
Bagur, A., et al. (2025)
British Journal of Radiology
Read Summary ▾
Manual srT1, a standardized biomarker of pancreatic fibro-inflammation, showed excellent intra- and inter-observer reproducibility and strong scan–rescan reliability. A semi-automated workflow further improved scan–rescan agreement.
Utility and cost-effectiveness of LiverMultiScan for MASLD diagnosis: a real-world multi-national randomised clinical trial
Shumbayawonda E., et al. (2025)
Communications Medicine
Read Summary ▾
Incorporating LiverMultiScan into the MASLD diagnostic pathway is cost-effective, significantly reduces the number of specialist appointments, patient assessments, and rate of diagnosis without increasing other liver-related health care resource use. cT1 also correctly classified 50% of patients without MASH with fibrosis who could avoid biopsy. Standardized adoption of LiverMultiScan can streamline clinical pathways, lower costs, and improve long-term management.
MRI-serum–based score accurately identifies patients undergoing liver transplant without rejection avoiding the need for liver biopsy: A multisite European study
Schaapman, J., et al. (2025)
Liver Transplantation
Read Summary ▾
Using multiparametric MRI metrics alongside routine blood markers supports identification of liver transplant patients without rejection, enabling many to avoid a liver biopsy. Findings support a practical, non-invasive pathway to monitor graft health and reduce unnecessary invasive procedures.
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study
Harrison, S., et al. (2025)
Journal of Hepatology
Read Summary ▾
In a 12-week MASLD trial, pemvidutide (a GLP-1/glucagon dual agonist) markedly reduced liver fat and improved cT1 versus placebo, alongside improvements in body weight and liver enzymes. A high proportion achieved clinically meaningful cT1 reductions. Treatment was well tolerated without serious adverse events, supporting pemvidutide as a promising therapy.
Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD
Moolla, A., et al. (2025)
JHEP Reports
Read Summary ▾
In this randomised control trial in people with MASLD without diabetes, LiverMultiScan monitored improvements in liver fat and liver disease activity following 12-week treatment with liraglutide, and the subsequent rebound after cessation. A low-calorie diet of similar duration achieved equivalent improvements.
Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD
Moolla A. (2025)
JHEP Reports
Read Summary ▾
In randomised control trial in MASLD patients without diabetes, LiverMultiScan monitored improvements in liver fat and liver disease activity following 12-week liraglutide treatment. Low-calorie diet achieved equivalent improvements.
A fasting-mimicking diet programme reduces liver fat and liver inflammation/fibrosis measured by magnetic resonance imaging in patients with type 2 diabetes. A fasting-mimicking diet programme reduces liver fat and liver inflammation/fibrosis measured by Magnetic Resonance Imaging in patients with type 2 diabetes
Van Den Burg., et al. (2025)
Clinical Nutrition
Read Summary ▾
A 12-month fasting-mimicking diet programme reduced liver fat (MRI-PDFF) and inflammation/fibrosis (cT1) in type 2 diabetes patients. Improvements in cT1 and PDFF correlated with reductions in HbA1c, fasting glucose, triglycerides, weight, and total cholesterol. This dietary approach shows promise as an adjunct therapy to standard diabetes care.
Repeatability, reproducibility, and observer variability of body composition assessment with single-slice lumbar MRI
Nowak, M., et al. (2025)
Discover imaging
Read Summary ▾
Single-slice MRI at the L3 vertebral level provides accurate and reproducible area measurements of fat and muscle across diverse body types, multiple MRI scanner field strengths, and manufacturers. The measurements are consistent between trained analysts and experienced radiologists.
Quantitative liver function imaging and whole genome sequencing – Effective modalities for a new era in personalised decision-making for operable colorectal liver metastases?
Welsh F., et al. (2025)
HPB
Read Summary ▾
In the Precision1 trial, preoperative mpMRI and whole-genome sequencing (WGS) informed personalized surgery for operable colorectal liver metastases. mpMRI frequently influenced surgical plans (e.g., embolization, parenchymal-sparing or more extensive resections, weight management). WGS provided therapeutic and prognostic insights, supporting tailored, multidisciplinary decision-making.
Head-to-head comparison among FAST, MAST and multiparametric MRI-based new score in diagnosing at-risk MASH
Imajo, K., et al. (2024)
European Radiology
Read Summary ▾
Two new MRI-based scoring strategies—single-step MPcT (MRE+PDFF+cT1) and two-step M-PcT (LSM by MRE then PDFF with cT1)—were evaluated to detect at-risk MASH. M-PcT showed superior diagnostic accuracy over FAST, MAST, and MPcT. PDFF plus cT1 also performed strongly for diagnosing active MASH and severe hepatic inflammation, outperforming FAST and MAST scores.
Liver magnetic resonance imaging, non-alcoholic fatty liver disease and metabolic syndrome risk in pre-pubertal Mexican boys
Alonso. D.C., et al. (2024)
Scientific Reports
Read Summary ▾
Multiparametric MRI assessed liver fat (PDFF) and fibroinflammation (cT1) in Hispanic prepubertal boys at risk for MASLD. Despite normal transaminases, mpMRI identified MASLD/MASH, with higher cT1/PDFF in those with metabolic risk factors. Elevated cT1 aligned with insulin resistance, supporting mpMRI, particularly cT1, for routine MASLD screening of high-risk pediatric groups.